Physician profile
Mohammed K Zahra
NPI 1114011939
$2,255.20
in general payments reported to CMS, 2019-2025
32 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $183 · 2021: $150 · 2022: $394 · 2023: $353 · 2024: $279 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $467.05 | 2019-2025 | Carvykti, Tecvayli, Darzalex |
| Incyte Corporation | $248.03 | 2019-2023 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $151.28 | 2019-2020 | |
| Eisai INC. | $131.23 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $131.17 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $130.25 | 2019-2022 | |
| Exelixis INC. | $119.49 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $106.77 | 2019-2020 | |
| Amgen INC. | $75.82 | 2019-2020 | |
| Celgene Corporation | $69.12 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.13 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $61.76 | 2019-2021 | |
| Seagen INC. | $50.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $43.67 | 2024 | Xarelto |
| Siemens Medical Solutions USA, INC. | $37.92 | 2024 | Somatom Go.Top, Artis Zeego |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $37.37 | 2025 | Eligard |
| Regeneron Healthcare Solutions, INC. | $34.35 | 2025 | Libtayo |
| Dova Pharmaceuticals | $32.98 | 2019-2020 | |
| Immunocore Limited | $32.80 | 2024 | Kimmtrak |
| Myriad Genetic Laboratories, INC. | $29.04 | 2022 | |
| W. L. Gore & Associates, INC. | $25.67 | 2025 | Gore Viatorr Tips Endoprosthesis With Controlled Expansion |
| Alnylam Pharmaceuticals INC. | $24.98 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.21 | 2019 | |
| Clovis Oncology, INC. | $17.51 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.04 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.40 | 2019 | |
| Lilly USA, LLC | $14.32 | 2019 | |
| Puma Biotechnology, INC. | $13.67 | 2019 | |
| Karyopharm Therapeutics INC. | $13.48 | 2023 | Xpovio |
| Array Biopharma INC | $13.25 | 2022 | |
| Coherus Oncology, INC. | $12.52 | 2020 | |
| Genzyme Corporation | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Zahra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.